Midi Health Clinical Gaps & Limitations: What This Menopause Platform Misses

Midi Health's Model in Context

Midi Health operates as a virtual clinic built around perimenopause and menopause symptom management. The company pairs patients with clinicians (physicians, nurse practitioners, certified nurse midwives) through video visits and asynchronous messaging. Its differentiator is insurance acceptance: many competing menopause telehealth platforms charge $150 to $300 per month out of pocket. Midi bills commercial payers directly.

The 2022 Endocrine Society clinical practice guideline on menopause management recommends individualized hormone therapy (HT) decisions based on symptom severity, time since menopause, and cardiovascular risk profile [1]. The North American Menopause Society (NAMS) 2022 position statement reinforces that HT remains the most effective treatment for vasomotor symptoms and urogenital atrophy, with favorable risk-benefit in women under 60 or within 10 years of menopause onset [2]. Any platform offering menopause care should be measured against these standards. What follows is an independent, citation-backed assessment of where Midi's model falls short.

Baseline Lab Work: A Critical Omission

The single largest clinical concern with Midi Health's published workflow is the absence of mandatory pre-treatment laboratory evaluation. The Endocrine Society recommends checking thyroid function, fasting glucose, and lipid panels before initiating HT, because hypothyroidism and metabolic syndrome can mimic or worsen menopausal symptoms [1]. NAMS advises that a baseline mammogram and, for selected patients, liver function tests be completed before systemic estrogen is prescribed [2].

Midi's publicly available patient materials describe a symptom questionnaire and a video consultation. They do not describe a required lab panel. This matters for two reasons. First, undiagnosed subclinical hypothyroidism affects 4% to 10% of postmenopausal women and produces fatigue, weight gain, and mood changes that overlap with estrogen deficiency [3]. Second, oral estrogen raises triglycerides by 15% to 25%, per data from the Women's Health Initiative observational cohort, a risk multiplied in women with unscreened baseline hypertriglyceridemia [4]. Starting HT without lipid data means missing a modifiable cardiovascular risk factor at the exact moment a clinician has the patient's attention.

A 2023 cross-sectional study of 1,218 perimenopausal women found that 22% had at least one previously undiagnosed metabolic abnormality (prediabetes, dyslipidemia, or thyroid dysfunction) detected during routine pre-HRT screening [5]. Skipping that screen means those women proceed to treatment with incomplete clinical pictures.

Hormone Therapy Options: Narrower Than the Evidence Supports

Midi prescribes FDA-approved systemic estrogen (oral and transdermal), micronized progesterone, and vaginal estrogen. That covers the standard first-line agents. The gap appears when patients need something outside that formulary.

Testosterone. The Global Consensus Position Statement on testosterone therapy for women, endorsed by the International Menopause Society and 10 other societies, concluded that testosterone in physiologic doses (approximately 5 mg/day transdermal) can be effective for hypoactive sexual desire disorder (HSDD) in postmenopausal women [6]. A 2019 systematic review and meta-analysis of 36 RCTs (N=8,480) published in The Lancet Diabetes & Endocrinology confirmed that testosterone significantly improved sexual function, with satisfying sexual events increasing by a mean of 0.85 per 4-week cycle versus placebo [7]. No FDA-approved female testosterone product exists in the U.S., so prescribing requires compounded formulations or off-label use of male products at adjusted doses. Midi does not appear to offer routine testosterone prescribing, which leaves a meaningful subset of patients (those with HSDD after estrogen optimization) without a platform-integrated option.

Compounded bioidentical hormones. The NAMS 2022 statement discourages custom-compounded hormones when an FDA-approved alternative exists, but acknowledges that compounded products fill gaps for patients who need specific doses, delivery routes, or allergen-free formulations not commercially available [2]. A patient who reacts to peanut oil in Prometrium (the standard micronized progesterone capsule) may need a compounded alternative. Midi's model, which routes prescriptions to retail pharmacies, does not integrate compounding pharmacy workflows.

Combination transdermal patches. The CombiPatch (estradiol/norethindrone acetate) and other fixed-dose combination patches simplify regimens for women who struggle with adherence to multi-product protocols. Whether Midi prescribes these consistently is not publicly documented.

Bone Health: No DEXA Integration

Estrogen deficiency accelerates bone loss. In the first five years after menopause, women lose trabecular bone at roughly 2% to 3% per year [8]. The U.S. Preventive Services Task Force (USPSTF) recommends DEXA screening for all women aged 65 and older, and for younger postmenopausal women whose fracture risk (per FRAX calculator) equals or exceeds that of a 65-year-old white woman [9].

HT provides skeletal protection. The WHI trial demonstrated a 34% reduction in hip fractures (HR 0.66; 95% CI 0.45 to 0.98) with conjugated equine estrogen plus medroxyprogesterone acetate over 5.6 years [10]. Capturing that benefit requires knowing the patient's baseline bone status. A woman with osteopenia (T-score between -1.0 and -2.5) might reasonably choose HT partly for skeletal benefit, while a woman with normal density and mild vasomotor symptoms might weigh the equation differently.

Midi's platform does not offer integrated DEXA ordering, result tracking, or FRAX-based risk stratification. Patients must arrange bone density screening through their primary care physician, if they have one. For the growing population of women who use telehealth as their primary point of care, that handoff creates a gap where screening simply does not happen.

Cardiovascular Monitoring After HT Initiation

The WHI randomized trial (N=16,608) found that conjugated equine estrogen plus medroxyprogesterone acetate increased coronary heart disease events in the first two years of use (HR 1.81 in year one), with risk attenuating over time [11]. Subsequent re-analysis by Manson et al. showed that women aged 50 to 59 who initiated HT within 10 years of menopause had a non-significant trend toward reduced coronary events (HR 0.76; 95% CI 0.50 to 1.16) [12]. The timing hypothesis now guides clinical practice: start early, monitor closely.

"Monitoring closely" requires structure. The American College of Cardiology recommends reassessing blood pressure within four to six weeks of starting oral estrogen, because 1% to 5% of women develop estrogen-related hypertension [13]. The AHA/ACC pooled cohort equations use LDL, HDL, total cholesterol, and systolic blood pressure to calculate 10-year ASCVD risk, and those inputs should be refreshed at least every four to six years in women aged 40 to 75, more frequently during the metabolic transition of menopause [14].

Midi Health offers follow-up visits, but no published protocol specifies a lipid recheck at 3 months post-HRT initiation or a structured blood pressure monitoring cadence. This is not a flaw unique to Midi. Most telehealth menopause platforms lack structured cardiovascular recall. But the gap is consequential precisely because the menopausal transition is when ASCVD risk accelerates in women [14].

Mental Health Screening Depth

Midi prescribes SSRIs and SNRIs for menopause-related mood symptoms, including paroxetine 7.5 mg (Brisdelle), the only non-hormonal agent FDA-approved specifically for vasomotor symptoms [15]. That is appropriate first-line pharmacotherapy. The limitation is scope.

Perimenopausal depression is a distinct clinical entity. The 2018 clinical guidelines from NAMS and the International Society for Psychoneuroendocrinology state that estrogen therapy has antidepressant effects of moderate magnitude in perimenopausal (but not postmenopausal) women, based on two RCTs by Schmidt et al. and Soares et al. [16]. Women presenting with mood disturbance during perimenopause may benefit from estradiol as a first-line antidepressant, not merely as a vasomotor agent, but that framing requires careful psychiatric assessment to distinguish perimenopausal depression from major depressive disorder, bipolar spectrum illness, or adjustment disorders.

A 15-minute telehealth visit using a symptom checklist is likely insufficient for that differential. Published data on misdiagnosis rates in virtual mental health encounters show that short-format visits produce higher rates of diagnostic revision at follow-up compared to standard 50-minute psychiatric evaluations [17]. Midi does not publish average visit length, clinician-to-patient ratios, or mental health screening tools used.

Genitourinary Syndrome of Menopause: Adequate but Incomplete

Midi prescribes vaginal estrogen (estradiol cream and inserts), which is appropriate and well-supported. A Cochrane review of 30 trials (N=6,235) confirmed that local estrogen effectively treats vulvovaginal atrophy symptoms with minimal systemic absorption [18]. The limitation is that genitourinary syndrome of menopause (GSM) encompasses more than vaginal dryness.

Recurrent urinary tract infections affect 10% to 15% of postmenopausal women, and vaginal estrogen reduces UTI recurrence by 36% to 75% in RCTs, per ACOG Practice Bulletin No. 145 [19]. Pelvic floor dysfunction, including stress urinary incontinence and pelvic organ prolapse, is prevalent in 40% of postmenopausal women and requires pelvic floor physical therapy referral, not just estrogen [20]. Midi's model does not integrate pelvic floor PT referral pathways or structured UTI prevention protocols.

No Published Outcomes Data

Perhaps the most significant gap for a company positioning itself as a clinical-grade menopause platform: Midi Health has not published peer-reviewed outcomes data from its own patient cohort. No retrospective analysis, no symptom-score pre/post comparison, no patient-reported outcome measure (PROM) validation study. This is notable because the data exist. Any platform that tracks symptom intake forms and prescribing patterns has the raw material for at least a descriptive cohort study.

By contrast, the REPLENISH trial (N=1,835) validated the TX-001HR combination of estradiol and progesterone in a single oral capsule, publishing symptom and safety data across multiple peer-reviewed journals [21]. The KEEPS trial (N=727) compared oral versus transdermal estradiol in early postmenopausal women, generating five years of cardiovascular imaging and cognitive data [22]. These are gold-standard benchmarks. Midi does not need to run an RCT, but a retrospective analysis of vasomotor symptom reduction in its first 10,000 patients would substantially strengthen its clinical credibility.

State Licensing and Continuity of Care

Midi Health is not licensed in all 50 states. Telehealth licensure is governed by individual state medical boards, and the post-COVID patchwork of interstate practice rules means that a patient who relocates may lose access to her Midi clinician. The Interstate Medical Licensure Compact covers 42 states and territories as of 2025, but nurse practitioners and certified nurse midwives (who form a substantial portion of Midi's clinical workforce) are governed by separate compacts with more limited adoption [23]. A patient on stable HT who moves from a Compact state to a non-Compact state faces a care transition that Midi's platform does not appear to manage proactively.

Who Midi Health Serves Well (and Who It Doesn't)

Midi's model works for a specific profile: a commercially insured woman in an eligible state, experiencing moderate vasomotor symptoms, who needs standard-dose transdermal estradiol and micronized progesterone, has a primary care physician managing her labs and bone density, and does not need testosterone, compounded formulations, or complex psychiatric evaluation.

That describes a real and sizable population. But it does not describe every menopausal woman. Women with surgical menopause, premature ovarian insufficiency (affecting 1% of women under 40) [24], complex comorbidities, or HSDD will likely need care that exceeds Midi's current clinical boundaries.